Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB092 in Early Alzheimer's Disease
NCT03352557Phase 2Terminated
- Sponsor
- Biogen
- Start
- May 2018
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of gosuranemab in Alzheimer's disease (AD) (4 arms), sponsored by Biogen. Primary endpoint: Percentage of Participants With Adverse Events and Serious Adverse Events. Started May 2018; status: terminated.
02
Drugs
gosuranemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03352557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03352557.